Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Drug Discovery
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 308731
Licensor, a non-profit health care organization, grants to Licensee, under Licensors one-half ownership interest in the Patent Rights, subject to the rights granted under a separate Party License, the worldwide right and exclusive license, with the right to sublicense, to import. make, have made, use, lease, offer for sale, sell and otherwise export the Licensed Products, and to practice the Licensed Processes, in the Territory for the Field of Use during the Term, unless sooner terminated as provided in this Agreement.
The patent applications include 61/221,541; 61/240,616; 61/316,267; 12/826,084; 61/434,818; 13/355,468; 61/589,267; and, 61/609,171.
Streptococcus pneumoniae (pneumococcus) is a Gram-positive bacterium that is responsible for the majority of community-acquired pneumonia. It is a commensal organism in the human respiratory tract, meaning that it benefits from the human body, without harming it
Licensee has rights to Patt Vaccine Sustems that include a non-exclusive right to sublicense, to develop, make or have made, and use a pneumococcal T cell based protein vaccine in the world and (ii) use market, promote, distribute and sell a pneumococcal T cell-based protein vaccine in Developing Countries.
Licensee has developed and/or controls a high-throughput system for in vitro screening of proven effectors of immunity ( e.g. libraries of efficacious T cells) to identify their specific target antigens from the complete proteome of any disease-causing agent, the High Throughput System. It has determined that a whole cell vaccine (WCV) made from killed unencapsulated pncumococcal cells, as well as purified antigens, can protect animals against colonization via CD4 + T Hl7 responses.
IPSCIO Record ID: 375114
Streptococcus pneumoniae is a bacteria that is a major cause of pneumonia. It can spread in persons carrying the bacteria in their upper respiratory tracts by direct person-to-person contact via respiratory droplets.
IPSCIO Record ID: 375061
BWV-201 is a live attenuated serotype-independent intranasal vaccine candidate for S. pneumoniae induced AOM (Acute Otitis Media). BWV-201 has the ability to transiently colonize the nasopharyngeal cavity and significantly decrease the incidence of AOM and sinusitis in animal models. The vaccine candidate is derived from the noninvasive serotype 19F strain BHN97.
9,265,819 – Live, attenuated Streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease
Streptococcus pneumoniae is the main cause of community acquired pneumonia and meningitis in children and the elderly, and of sepsis in those infected with HIV.
IPSCIO Record ID: 308733
For the Exclusive License, the Licensor of Sweden grants an exclusive license, with the right to grant sublicense, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith.
For the Time-Limited Exclusive License, Licensor grants an exclusive, limited in time license, with the right to grant sublicenses, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Time-Limited Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith.
For the Non-Exclusive License, Licensor grants a nonexclusive license, with the right to grant sublicenses, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Non-Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith; provided, however, that with respect to the Joint Technology.
Licensee Antigen means any antigen (a) owned or otherwise Controlled by Licensee and (b) believed to trigger an immune response causing the production of antibodies and/or cytokine or T-cell responses in humans as a defense against or treatment for a Disease Field.
Licensed Adjuvant means an adjuvant Controlled by Licensor which incorporates or is developed from Matrix-A, Matrix-C and/or Matrix-M technology.
Licensed Product means any vaccine product containing both the Licensed Adjuvant and one or more Licensee Antigens; provided, however a Licensed Product may include a combination vaccine product for two or more Disease Fields but not a combination vaccine product for a Disease Field and a field that is not a Disease Field.
Matrix-A means a component of the Matrix M adjuvant that is produced by mixing together HPLC-purified fraction A from Quillaja saponin bark, cholesterol and phosphatidyl choline to form Iscom particles.
Matrix-C means a component of the Matrix M adjuvant that is produced by mixing together HPLC-purified fraction C from Quillaja saponin bark, cholesterol and phosphatidyl choline to form Iscom particles.
Matrix-M means a suspension of Matrix A and Matrix C particles that are combined in varying ratios of Matrix A to Matrix C.
The agreement grants Licensee license to two patent families, to import, make, have made, use, sell, offer for sale and otherwise exploit licensed vaccine products containing an adjuvant which incorporates or is developed from Matrix-A, Matrix-C and/or Matrix-M technology, in the fields of HSV and chlamydia, and the time-limited exclusive fields of Neisseria gonorrhoeae, cytomegalovirus, or CMV, and Mycobacterium tuberculosis.
Licensee is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today, using a proprietary discovery platform, ATLAS, to rapidly design vaccines that act through T cell (or cellular) immune responses, in contrast to approved vaccines, which are designed to act primarily through B cell (or antibody) immune responses. Licensee is also developing a second T cell vaccine candidate, GEN-004 for pneumococcus, a leading cause of infectious disease mortality worldwide.
IPSCIO Record ID: 308732
The College grants to Licensee a non-exclusive, worldwide, license under its rights in and to the College Technology Transfer Materials solely for use in identifying, discovering, developing, making, having made, using, marketing, offering for sale, selling, having sold and importing any Type I Licensed Product or Type II Licensed Product.
Type I Licensed Product shall mean any product, the manufacture, use, sale, marketing or importation of which falls within the scope of a Valid Claim in the country in which it is manufactured, used, sold, marketed or imported. Type II Licensed Product' shall mean any product that is not a Type I Licensed Product, but is identified or discovered through the use of a Licensed Method.
Licensed Services shall mean any service provided for or on behalf of a third party on a fee-for-service basis that entails the practice of a Licensed Method.
Materials transferred include
– Chlamydia libraries (donor library and expression library with and without cLLO)
– pDEST-SL8 expression vector
– Plasmids and E. Coli Strains
– T cell Lines
– Other Cell Lines, and,
– Protocols as follows
1. Gateway cloning
2. CE6 phage prep
3. Library induction
4. Library screening
5. Chlamydia growth and prep
6. T cell expansion (multiple protocols)
7. APC preps
8. Chlamydia infection ( cell line and mouse)
9. B3Z assay for library validation
10. ICS assay for antigen presentation
Chlamydia, or more specifically a chlamydia infection, is a sexually transmitted infection caused by the bacterium Chlamydia trachomatis.
Licensee is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today.
IPSCIO Record ID: 356264